How antibody therapy clears Alzheimer’s plaques: Key immune mechanism identified

Lecanemab, sold under the name Leqembi, is a monoclonal antibody therapy for Alzheimer’s disease that clears toxic amyloid plaques and delays cognitive decline. Researchers from VIB and KU Leuven have now demonstrated the mechanism behind it for the first time.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup